GHRP-6
🚚 Ships same day if ordered before 2PM EST
One of the original growth hormone releasing peptides. GHRP-6 is a hexapeptide that stimulates GH release through ghrelin receptor agonism and is widely used in GH secretagogue research alongside GHRH analogs.
Compound Profile
Pharmaceutical Data Sheet
Mechanism of Action
How GHRP-6 Works
GHRP-6 is a synthetic hexapeptide that acts as a potent agonist at the growth hormone secretagogue receptor type 1a (GHS-R1a), the same receptor targeted by endogenous ghrelin. Upon binding, it triggers a calcium-dependent signaling cascade in anterior pituitary somatotrophs, producing robust growth hormone release. GHRP-6 is distinguished from other GHRPs by its strong appetite-stimulatory properties mediated through hypothalamic ghrelin pathway activation.
- Direct agonism at pituitary GHS-R1a
- Triggers calcium-mediated GH exocytosis
- Complementary to GHRH-R signaling (cAMP pathway)
- Produces GH pulses mimicking natural secretion pattern
- Activates hypothalamic appetite centers via GHS-R1a
- Stimulates neuropeptide Y (NPY) and AgRP neurons
- Increases gastric motility and acid secretion
- Strongest appetite effect among GHRP family
- Elevated GH drives hepatic IGF-1 synthesis
- IGF-1 mediates anabolic and lipolytic effects
- IGFBP-3 elevation extends IGF-1 bioactivity
- Fat metabolism enhancement via GH-mediated lipolysis
GHRP-6 binds the GHS-R1a receptor on pituitary somatotrophs, activating the Gq/11 G-protein. This stimulates phospholipase C (PLC), generating IP3 which triggers calcium release from intracellular stores. The resulting calcium spike promotes GH granule fusion and exocytosis. This pathway is complementary to the cAMP/PKA cascade activated by GHRH, explaining the synergistic GH response when GHRP-6 is combined with CJC-1295 w/o DAC.
Smith RG et al., Endocr Rev (2005): Growth hormone secretagogue receptor family members and ligands.
Preclinical Findings
Research Models
Clinical Data
GH Pulse Amplification via GHS-R1a Agonism
Research demonstrates that GHRP-6 produces dose-dependent GH release, with peak plasma GH concentrations achieved within 15–30 minutes. When combined with a GHRH analog, the GH response is synergistic — significantly exceeding the additive effects of either agent alone.
Bowers CY, J Clin Endocrinol Metab (1994): GH releasing peptides — mechanism of action.
Human pharmacokinetic and rodent dose-response studies
Research Outcomes
Key Research Success Metrics
Safety Profile
Research Safety Notes
- Transient appetite increase is expected and dose-dependent — mediated by hypothalamic ghrelin signaling
- Mild cortisol and prolactin elevation observed at higher doses — less selective than GHRP-2
- No carcinogenic or mutagenic signals in preclinical safety studies
- GH desensitization may occur with continuous (non-pulsatile) administration — pulsed protocols preferred
- Well-characterized safety profile across >20 years of research use
For research use only. GHRP-6 modulates the GH axis via ghrelin receptor agonism. Research subjects may exhibit increased appetite. Not for human therapeutic use.
About GHRP-6
One of the original growth hormone releasing peptides. GHRP-6 is a hexapeptide that stimulates GH release through ghrelin receptor agonism and is widely used in GH secretagogue research alongside GHRH analogs.
All PureAmino Research compounds are manufactured to research-grade standards and independently tested by Janoshik Analytical & Kovera Labs. The Certificate of Analysis for this compound includes full HPLC chromatography data, mass spectrometry confirmation, net purity percentage, and net content verification.
Research Use Only
This product is strictly for in vitro research and laboratory use only. Not for human or veterinary consumption. By purchasing, you confirm use in a controlled research setting.
